keyword
Keywords nausea and vomitting in pallia...

nausea and vomitting in palliative care

https://read.qxmd.com/read/38532121/symptom-burden-and-relief-in-palliative-care-units-of-german-comprehensive-cancer-center-and-other-hospitals
#1
JOURNAL ARTICLE
Julia Berendt, Sarah Brunner, Maria Heckel, Mitra Tewes, Christoph Ostgathe, Susanne Gahr
PURPOSE: The National Hospice and Palliative Registry contains patient data from German hospice and palliative care facilities about symptoms. The aim of the study at hand is to differentiate symptom burden of patients in palliative care units between Comprehensive Cancer Center (CCC) and other hospitals regarding symptom burden and relief of patients in palliative care units. METHODS: The registry analysis provided data of patients in palliative care units (2014-2018)...
March 27, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38481215/a-dutch-paediatric-palliative-care-guideline-a-systematic-review-and-evidence-based-recommendations-for-symptom-treatment
#2
JOURNAL ARTICLE
Kim C van Teunenbroek, Renée L Mulder, Inge M L Ahout, Karen G C B Bindels-de Heus, Catharina M Delsman-van Gelder, Annemie F S Galimont-Collen, Marinka A R de Groot, Katja M J Heitink-Polle, Jeffry Looijestijn, Maarten O Mensink, Selma Mulder, Jolanda H Schieving, Antoinette Y N Schouten-van Meeteren, Johannes M A Verheijden, Hester Rippen, Brigitt C M Borggreve, Leontien C M Kremer, A A Eduard Verhagen, Erna M C Michiels
BACKGROUND: Children with life-threatening and life-limiting conditions can experience high levels of suffering due to multiple distressing symptoms that result in poor quality of life and increase risk of long-term distress in their family members. High quality symptom treatment is needed for all these children and their families, even more so at the end-of-life. In this paper, we provide evidence-based recommendations for symptom treatment in paediatric palliative patients to optimize care...
March 13, 2024: BMC Palliative Care
https://read.qxmd.com/read/38425636/palliative-stenting-for-gastric-outlet-obstruction-secondary-to-pancreatic-adenocarcinoma
#3
Dhruv Patel, Furqan A Bhullar, Ariana R Tagliaferri, Gabriel Melki, Matthew A Grossman
Pancreatic cancer is one of the most fatal malignancies due to its advanced stages at the time of presentation. Often, it is only diagnosed when patients present with late-stage complications, such as gastric outlet obstruction (GOO). Many patients experience a poor quality of life due to the side effects of GOO, such as persistent nausea, vomiting, and an inability to tolerate an oral diet, and as such, patients deteriorate quickly after their diagnosis. Because pancreatic cancer is diagnosed at advanced stages, many patients are not surgical candidates, and thus treatment is tailored for palliative measures...
January 2024: Curēus
https://read.qxmd.com/read/38417963/investigating-the-efficacy-and-safety-of-olanzapine-prophylaxis-for-opioid-induced-nausea-and-vomiting-jortc-pal20-a-study-protocol-for-an-open-label-single-arm-exploratory-study
#4
JOURNAL ARTICLE
Eriko Satomi, Tomomi Kobayashi, Ayaka Ishikawa, Sayaka Arakawa, Hiroto Ishiki, Koji Amano, Naomi Sakiyama, Keisuke Ariyoshi, Kota Kihara, Shunsuke Oyamada, Akio Mizushima
INTRODUCTION: In opioid therapy for cancer pain, opioid-induced nausea and vomiting (OINV) occur in 20%-40% of patients during initial opioid treatment or increasing opioid doses. OINV result in failure to achieve pain relief due to poor opioid adherence. Therefore, antiemetics are used to prevent OINV, but their efficacy and safety in this context have not yet been fully elucidated. Olanzapine is a promising antiemetic for the prophylaxis of chemotherapy-induced nausea and vomiting. METHODS AND ANALYSIS: This single-arm, single-centre exploratory study will evaluate the prophylactic antiemetic efficacy and safety of 5 mg olanzapine in patients with cancer pain who are withholding initial regular opioid therapy...
February 27, 2024: BMJ Open
https://read.qxmd.com/read/38417464/palliative-medicine-fellows-discussions-perceptions-and-training-regarding-medical-cannabis
#5
JOURNAL ARTICLE
Dylan R Sherry, Rushad Patell, Harry J Han, Laura E Dodge, Ilana M Braun, Mary K Buss
INTRODUCTION: Medical cannabis is increasingly considered for palliation of pain, nausea/vomiting, anorexia, and other symptoms. We aimed to determine whether training in hospice and palliative medicine (HPM) adequately prepares fellows to counsel patients about medical cannabis. METHODS: A previously validated questionnaire was adapted for HPM fellows. Domains included fellows' practices recommending cannabis and their knowledge of its effectiveness and risks compared with standard treatments...
February 26, 2024: Journal of Pain and Symptom Management
https://read.qxmd.com/read/38400861/adherence-to-antiemetic-guidelines-in-solid-cancer-patients-receiving-highly-emetogenic-chemotherapy-in-korea
#6
JOURNAL ARTICLE
Ryugyoung Lee, Minhee Ku, Nam Kyung Je
BACKGROUND: Highly emetogenic chemotherapy (HEC) is known to induce nausea and vomiting (CINV) in approximately 90% of cancer patients undergoing this regimen unless proper prophylactic antiemetics are administered. This study aimed to analyze the use of a three-drug prophylactic antiemetic regimen during the first cycle of chemotherapy and assess the compliance rate with the National Comprehensive Cancer Network (NCCN) guidelines. METHODS: This retrospective study utilized data from the National Inpatient Sample database from 2016 to 2020 provided by the Health Insurance Review and Assessment Service...
February 24, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38362443/appropriateness-of-mini-invasive-approaches-for-nausea-and-vomiting-refractory-to-medical-therapy-in-palliative-care-setting-a-case-report
#7
Chiara Casadio, Elisa Tassinari, Riccardo Carloni, Romina Rossi, Maria Valentina Tenti, Laura Fabbri, Marco Maltoni
INTRODUCTION: Nausea and vomiting are frequent multifactorial symptoms in oncological patients. These manifestations, mainly affecting the advanced disease stages, may lead to existential, psychological, and physical suffering, with a negative impact on the quality of life (QoL) of the individual and his family. The medical approach makes use of a wide range of drugs, with different antiemetic potency and various mechanisms of action, taking into account the etiology and the patient's response to the different therapeutic strategies...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38359528/do-older-patients-with-colorectal-cancer-experience-more-deterioration-in-health-related-quality-of-life-than-younger-patients-during-the-first-year-of-palliative-chemotherapy-a-prospective-real-world-observational-study
#8
JOURNAL ARTICLE
Ingunn Hatlevoll, Are K Kristensen, Tora S Solheim, Hege Elvebakken, Øyvind Salvesen, Line M Oldervoll, Arne Wibe, Eva Hofsli
INTRODUCTION: The primary aim was to evaluate changes in health-related quality of life (HRQoL) in a real-life population among younger (< 70 years) and older patients with metastatic colorectal cancer (mCRC) during the first year of palliative chemotherapy. The secondary aims were to assess the impact of chemo-break on HRQoL and to report overall survival (OS). MATERIALS AND METHODS: Patients with newly diagnosed mCRC, ≥ 18 years, and scheduled for first line palliative chemotherapy were included in this multicentre longitudinal observational study...
February 14, 2024: Journal of Geriatric Oncology
https://read.qxmd.com/read/38343467/the-use-of-cannabinoids-in-palliating-cancer-related-symptoms-a-narrative-review
#9
REVIEW
Jess Hatfield, Krishna Suthar, Tricia A Meyer, Lucas Wong
Despite uncertain efficacy, cannabinoids and derived products are becoming increasingly used in the field of palliative care for oncologic patients. Cannabinoids chiefly include psychoactive tetrahydrocannabinol (THC) and nonpsychoactive cannabidiol (CBD). Use of and research interest in THC, CBD, and combination THC/CBD products have increased in recent years, particularly after the Agriculture Improvement Act of 2018 made cannabis plants with <0.3% THC no longer controlled substances, and many states recently legalized THC use altogether...
2024: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/38316401/octreotide-for-long-lasting-malignant-bowel-obstruction-two-case-reports
#10
JOURNAL ARTICLE
Sebastiano Mercadante, Laura Tartaglia
BACKGROUND: Efficacy of the combination of octreotide and other drugs for the management of malignant bowel obstruction (MBO) has been well described. However, long-lasting stages with lack of stool emission are a challenging clinical condition of MBO that have never described. CASE DESCRIPTION: We describe two cases in which the addition of octreotide to supportive care measures, even given late after more than 3 weeks of no stool emission, resulted to be still effective in recovering the bowel transit...
January 2024: Annals of Palliative Medicine
https://read.qxmd.com/read/38255105/development-and-validation-of-an-auricular-acupuncture-protocol-for-the-management-of-chemotherapy-induced-nausea-and-vomiting-in-cancer-patients
#11
JOURNAL ARTICLE
Eliza Mara das Chagas Paiva, Caroline de Castro Moura, Denismar Alves Nogueira, Ana Cláudia Mesquita Garcia
Auricular acupuncture (AA) has been used to manage chemotherapy-induced nausea and vomiting (CINV). However, the application of the technique varies widely among the clinical trials that test its effectiveness. The aim of the present study was to develop and clinically validate an AA protocol for the management of CINV in cancer patients. This study was carried out in two stages: (1) development of the AA protocol for the management of CINV and (2) clinical validation of the protocol. The content validity of the protocol was determined by a panel of specialists, with an agreement rate ranging from 85...
January 16, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38227839/a-multicenter-retrospective-observational-study-analyzing-the-effect-of-polypharmacy-on-oxycodone-tolerability
#12
JOURNAL ARTICLE
Katsuya Makihara, Yoshihiro Yamamoto, Masayuki Miyazaki, Maho Taguchi, Junya Sato, Hisamitsu Takase, Yasuhito Uezono
Polypharmacy is becoming increasingly troublesome in the treatment of cancer. The aim of this study was to explore the effects of concomitant polypharmacy comprising drugs that inhibit CYP3A4 and/or CYP2D6 on the oxycodone tolerability in patients with cancer. We conducted a multicenter retrospective study encompassing 20 hospitals. The data used for the study were obtained during the first 2 wk of oxycodone administration. The incidence of oxycodone discontinuation or dose reductions due to side effects and oxycodone-induced nausea and vomiting (OINV) were compared between patients not treated with either inhibitor and those treated with concomitant CYP3A4 or CYP2D6 inhibitors...
January 16, 2024: Journal of Pain & Palliative Care Pharmacotherapy
https://read.qxmd.com/read/38178110/comparing-quality-indicator-rates-for-home-care-clients-receiving-palliative-and-end-of-life-care-before-and-during-the-covid-19-pandemic
#13
JOURNAL ARTICLE
Julia Kruizinga, Kathryn Fisher, Dawn Guthrie, Melissa Northwood, Sharon Kaasalainen
BACKGROUND: The consensus among Canadians with regards to end-of-life preferences is that with adequate support the majority prefer to live and die at home. PURPOSE: To compare quality indicator (QI) rates for home care clients receiving palliative and end-of-life care prior to and after the onset of the COVID-19 pandemic. METHODS: A retrospective population-based cohort design was used. Sixteen QIs informed by existing literature and a preliminary set of QIs recently evaluated by a modified Delphi panel were compared...
January 5, 2024: BMC Palliative Care
https://read.qxmd.com/read/38170327/prediction-of-gastrointestinal-symptoms-trajectories-using-omega-3-and-inflammatory-biomarkers-in-early-stage-breast-cancer-patients-receiving-chemotherapy
#14
JOURNAL ARTICLE
Daniela Arcos, Ding Quan Ng, Yu Ke, Yi Long Toh, Alexandre Chan
PURPOSE: Gastrointestinal (GI) symptoms are common among breast cancer patients undergoing chemotherapy, negatively impacting treatment outcomes and quality of life. Evidence points to inflammatory processes as the underlying cause of chemotherapy-associated GI symptoms. Relatedly, omega-3 (n-3) has been linked to anti-inflammatory processes. The primary objective of this study was to examine the associations between baseline n-3, baseline inflammatory markers and GI symptom progression in early-stage breast cancer patients receiving chemotherapy...
January 3, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38170261/discovering-different-acupoint-combinations-of-manual-or-electro-acupuncture-to-treat-chemotherapy-induced-nausea-and-vomiting-based-on-the-complex-networks-analysis
#15
JOURNAL ARTICLE
Yang Guo, Xinmeng Guo, Runchen Zhang, Yupei Cheng, Yi Liu, Dian Zeng, Jiang Wang, Bo Chen, Yi Guo
OBJECTIVES: The aim of this research was to find the acupoint combinations of manual and electro-acupuncture to treat chemotherapy-induced nausea and vomiting via the complex networks analysis. METHODS: We conducted searches using PubMed, ScienceDirect, MEDLINE, Ovid, spring, Wiley, EMBASE, the Chinese biomedicine database, VIP information network, and China National Knowledge Infrastructure from the establishment of the databases to the August, 2023. Information about titles, journals, interventions, and main acupoints was extracted using the self-established "acupoint for prevention CINV data base" powered by EpiData...
January 3, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38145979/palonosetron-for-prevention-of-delayed-chemotherapy-induced-nausea-and-vomiting-in-pediatric-patients-a-meta-analysis
#16
JOURNAL ARTICLE
Atsushi Yamaguchi, Yoshitaka Saito, Yoh Takekuma, Mitsuru Sugawara
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) are common adverse events in patients undergoing emetogenic chemotherapy. Palonosetron, a second-generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3 RA), has demonstrated non-inferiority to first-generation 5-HT3 RAs for CINV in pediatric patients. Although palonosetron has a long half-life and prolonged antiemetic action, its efficacy against delayed CINV in pediatric patients is not well understood. Therefore, this meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy of palonosetron for delayed CINV in pediatric patients...
December 26, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38129530/emetic-risk-classification-and-evaluation-of-the-emetogenicity-of-antineoplastic-agents-updated-mascc-esmo-consensus-recommendation
#17
JOURNAL ARTICLE
Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport, Christina H Ruhlmann, Paula Sayegh, Paul J Hesketh
PURPOSE: Our goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC/ESMO antiemetic update and classify their emetic potential. METHODS: The MASCC/ESMO Expert Panel classified the emetogenicity of the identified new antineoplastic agents based on nonsystematic reviews of randomized controlled trials, analysis of product labeling, and evaluation of emetic classification in other international guidelines and informal consensus...
December 22, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38127246/2023-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-high-emetic-risk-antineoplastic-agents
#18
JOURNAL ARTICLE
Jørn Herrstedt, L Celio, P J Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro
PURPOSE: This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016-2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m2 and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer. METHODS: A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed...
December 21, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38114821/2023-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-moderately-emetic-risk-antineoplastic-agents
#19
JOURNAL ARTICLE
Florian Scotté, Lee Schwartzberg, Hirotoshi Lihara, Matti Aapro, Richard Gralla, Paul J Hesketh, Karin Jordan, Ronald Chow, Jørn Herrstedt
PURPOSE: Review the literature to update the MASCC guidelines from 2015 for controlling nausea and vomiting with systemic cancer treatment of moderate emetic potential. METHODS: A systematic literature review was completed using Medline, Embase, and Scopus databases. The literature search was done from June 2015 to January 2023 of the management of antiemetic prophylaxis for anticancer therapy of moderate emetic potential. RESULTS: Of 342 papers identified, 19 were relevant to update recommendations about managing antiemetic prophylaxis for systemic cancer treatment regimens of moderate emetic potential...
December 20, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38110581/2023-updated-mascc-esmo-consensus-recommendations-controlling-nausea-and-vomiting-with-chemotherapy-of-low-or-minimal-emetic-potential
#20
JOURNAL ARTICLE
Ian Olver, Rebecca Clark-Snow, Christina H Ruhlmann, Maria-Angeles Garcia-Del-Barrio, Lee Schwartzberg, Bernardo Leon Rapoport, Franziska Jahn
PURPOSE: Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential. METHODS: A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%...
December 19, 2023: Supportive Care in Cancer
keyword
keyword
109476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.